ImmuPharma (LON:IMM) Shares Up 20.4% – Here’s What Happened

ImmuPharma plc (LON:IMM – Get Free Report) shares traded up 20.4% during trading on Friday. The stock traded as high as GBX 2.90 and last traded at GBX 2.90. 4,199,980 shares were traded during trading, an increase of 67% from the average daily volume of 2,518,765 shares. The stock had previously closed at GBX 2.40.

ImmuPharma Trading Up 20.4%

The company has a market cap of £18.10 million, a price-to-earnings ratio of -3.49 and a beta of 3.02. The firm’s fifty day simple moving average is GBX 3.46 and its 200 day simple moving average is GBX 4.48.

ImmuPharma (LON:IMM – Get Free Report) last announced its earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. As a group, sell-side analysts expect that ImmuPharma plc will post -339.00 EPS for the current year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.